Literature DB >> 22654926

Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee.

Danielle Rouleau1, Claude Fortin, Benoît Trottier, Richard Lalonde, Normand Lapointe, Pierre Côté, Jean-Pierre Routy, Marie-France Matte, Irina Tsarevsky, Jean-Guy Baril.   

Abstract

The appropriate use of antiretrovirals reduces morbidity and mortality caused by HIV infection. The present article provides health care professionals with a practical guide for the use of antiretrovirals. Therapy should be initiated based predominantly on clinical presentation and CD4 count, and should consist of three active drugs or at least two active drugs when this is not possible, as in cases of some treatment-experienced patients. This is the most effective way to achieve long-term suppression of viral replication. Selection of individual drugs in the regimen should consider the weight of the evidence supporting these choices, as well as their tolerability profiles and ease of use, the patients' comorbidities and treatment history. Treatment interruption is not recommended, either in aviremic patients or in those who have experienced virological failure. Instead, the therapeutic regimen should be adjusted to minimize side effects, promote adherence and suppress viral replication.

Entities:  

Keywords:  Antiretrovirals; HAART; HIV; Practical guide

Year:  2011        PMID: 22654926      PMCID: PMC3142594          DOI: 10.1155/2011/169045

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  89 in total

1.  HIV-associated lipodystrophy syndrome: A review of clinical aspects.

Authors:  Jean-Guy Baril; Patrice Junod; Roger Leblanc; Harold Dion; Rachel Therrien; Franãois Laplante; Julian Falutz; Pierre Côté; Marie-Nicole Hébert; Richard Lalonde; Normand Lapointe; Dominic Lévesque; Lyse Pinault; Danielle Rouleau; Cécile Tremblay; Benoãt Trottier; Sylvie Trottier; Chris Tsoukas; Karl Weiss
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

2.  Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.

Authors:  Manuel L Fernández Guerrero; Pablo Rivas; Mercedes Molina; Rosa Garcia; Miguel De Górgolas
Journal:  Clin Infect Dis       Date:  2005-06-22       Impact factor: 9.079

3.  A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

Authors:  Ulrik B Dragsted; Jan Gerstoft; Mike Youle; Zoe Fox; Marcello Losso; Jorge Benetucci; Dushyantha T Jayaweera; Armin Rieger; Johan N Bruun; Antonella Castagna; Brian Gazzard; Sharon Walmsley; Andrew Hill; Jens D Lundgren
Journal:  Antivir Ther       Date:  2005

4.  Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

Authors:  Sharon Walmsley; Anchalee Avihingsanon; Jihad Slim; Douglas J Ward; Kiat Ruxrungtham; Jason Brunetta; U Fritz Bredeek; Dushyantha Jayaweera; Carol Jean Guittari; Peter Larson; Malte Schutz; François Raffi
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

5.  Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Authors:  Angeles Jaén; Anna Esteve; Josep M Miró; Cristina Tural; Alexandra Montoliu; Elena Ferrer; Melcior Riera; Ferran Segura; Lluis Force; Omar Sued; Josep Vilaró; Isabel Garcia; Angels Masabeu; Jordi Altès; Bonaventura Coltet; Daniel Podzamczer; Javier Murillas; Gemma Navarro; Josep M Gatell; Jordi Casabona
Journal:  J Acquir Immune Defic Syndr       Date:  2008-02-01       Impact factor: 3.731

6.  A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

Authors:  Esteban Martínez; José A Arranz; Daniel Podzamczer; Montserrat Loncá; José Sanz; Patricia Barragán; Esteban Ribera; Hernando Knobel; Victor Roca; Félix Gutiérrez; José L Blanco; Josep Mallolas; Josep M Llibre; Bonaventura Clotet; David Dalmau; Ferran Segura; José R Arribas; Jaime Cosín; Pilar Barrufet; Esperanza Casas; Elena Ferrer; Adrià Curran; Alicia González; Judit Pich; Ana Cruceta; Joan A Arnaiz; José M Miró; José M Gatell
Journal:  J Acquir Immune Defic Syndr       Date:  2009-07-01       Impact factor: 3.731

7.  Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Authors:  José Valdez Madruga; Daniel Berger; Marilyn McMurchie; Fredy Suter; Denes Banhegyi; Kiat Ruxrungtham; Dorece Norris; Eric Lefebvre; Marie-Pierre de Béthune; Frank Tomaka; Martine De Pauw; Tony Vangeneugden; Sabrina Spinosa-Guzman
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

8.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Authors:  Kimberly Y Smith; Parul Patel; Derek Fine; Nicholaos Bellos; Louis Sloan; Philip Lackey; Princy N Kumar; Denise H Sutherland-Phillips; Cindy Vavro; Linda Yau; Paul Wannamaker; Mark S Shaefer
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

9.  Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Authors:  Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

10.  Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Authors:  Zoe Fox; Andrew Phillips; Cal Cohen; Jacquie Neuhaus; John Baxter; Sean Emery; Bernard Hirschel; Kathy Huppler Hullsiek; Christoph Stephan; Jens Lundgren
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

View more
  5 in total

1.  Challenges in initiating antiretroviral therapy in 2010.

Authors:  Cécile L Tremblay; Jean-Guy Baril; David Fletcher; Donald Kilby; Paul Macpherson; Stephen D Shafran; Mark W Tyndall
Journal:  Can J Infect Dis Med Microbiol       Date:  2010-08       Impact factor: 2.471

2.  Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.

Authors:  Marina B Klein; Jean-Guy Baril; Marc-André Charron; Claude Fortin; Richard Lalonde; Marie-France Matte; Marc Poliquin; Annie Talbot; Rachel Therrien; Cécile Tremblay; Benoît Trottier; Irina Tsarevsky; Jean-Pierre Villeneuve
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

3.  Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Authors:  Barbara A Rath; Richard A Olshen; Jerry Halpern; Thomas C Merigan
Journal:  Viruses       Date:  2012-08-07       Impact factor: 5.048

Review 4.  Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals.

Authors:  Jonathan Underwood; Alan Winston
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

5.  Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens.

Authors:  P G Clay; S Nag; C M Graham; S Narayanan
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.